Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4292-4297

  Allou, Nicolas ^a   Cambau, Emmanuelle ^a,b   Massias, Laurent ^c   Chau, Françoise ^a   Fantin, Bruno ^a,d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; QNRA1 PROTEIN; QNRS1 PROTEIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL GENE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM MUTANT; BLADDER; CONTROLLED STUDY; DISEASE MODEL; DRUG BLOOD LEVEL; DRUG EXPOSURE; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; IN VITRO STUDY; KIDNEY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PYELONEPHRITIS; SINGLE DRUG DOSE; STRAIN DIFFERENCE;

ANIMALS; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; DNA GYRASE; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; FLUOROQUINOLONES; MICE; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 70349318571     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01664-08     Document Type: Article

References (40)

1. Blondeau, J. M., X. Zhao, G. Hansen, and K. Drlica. 2001. Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:433-438.
2. Brunner, M., H. Stab, J.-G. Möller, C. Schrolnberger, B. Erovic, U. Hollenstein, M. Zeitlinger, H. G. Eichler, and M. Müeller. 2002. Target site concentrations of ciprofloxacin after single intravenous and oral doses. Antimicrob. Agents Chemother. 46:3724-3730.
3. Cambau, E., C. Lascols, W. Sougakoff, C. Bebear, R. Bonnet, J. D. Cavallo, L. Gutmann, M. C. Ploy, V. Jarlier, C. J. Soussy, and J. Robert. 2006. Occurrence of qnrA-positive clinical isolates in French teaching hospitals during 2002-2005. Clin. Microbiol. Infect. 12:1013-1020.
4. Cesaro, A., R. R. Bettoni, C. Lascols, A. Merens, C. J. Soussy, and E. Cambau. 2008. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes. J. Antimicrob. Chemother. 61:1007-1015.
5. Chenia, H. Y., B. Pillay, and D. Pillay. 2006. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens. J. Antimicrob. Chemother. 58:1274-1278.
6. CLSI. 2005. Performance standards for antimicrobial susceptibility testing; 15th informational supplement. Document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Corkill, J. E., J. J. Anson, and C. A. Hart. 2005. High prevalence of the plasmid-mediated quinolone resistance determinant qnrA in multidrug-resistant Enterobacteriaceae from blood cultures in Liverpool, UK. J. Antimicrob. Chemother. 56:1115-1117.
8. Crump, J. A., K. Kretsinger, K. Gay, R. M. Hoekstra, D. J. Vugia, S. Hurd, S. D. Segler, M. Megginson, L. J. Luedeman, B. Shiferaw, S. S. Hanna, K. W. Joyce, E. D. Mintz, F. J. Angulo, et al. 2008. Clinical response and outcome of infection with Salmonella enterica serotype Typhi with decreased susceptibility to fluoroquinolones: a United States foodnet multicenter retrospective cohort study. Antimicrob. Agents Chemother. 52:1278-1284.
9. Endimiani, A., F. Luzzaro, M. Perilli, G. Lombardi, A. Coli, A. Tamborini, G. Amicosante, and A. Toniolo. 2004. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin. Infect. Dis. 38:243-251.
10. European Commission. 1986. Directive for the protection of vertebrate animals used for experiments and other scientific purposes (86/609/EEC). Off. J. Eur. Comm. L 358:1-29.
11. Forrest, A., D. E. Nix, C. H. Ballow, T. F. Goss, M. C. Birmingham, and J. J. Schentag. 1993. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081.
12. Fuursted, K., and H. Schumacher. 2002. Significance of low-level resistance to ciprofloxacin in Klebsiella pneumoniae and the effect of increased dosage of ciprofloxacin in vivo using the rat granuloma pouch model. J. Antimicrob. Chemother. 50:421-424.
13. Goettsch, W., W. van Pelt, N. Nagelkerke, M. G. Hendrix, A. G. Buiting, P. L. Petit, L. J. Sabbe, A. J. van Griethuysen, and A. J. de Neeling. 2000. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J. Antimicrob. Chemother. 46:223-228.
14. Gonzalez, M. A., F. Uribe, S. D. Moisen, A. P. Fuster, A. Selen, P. G. Welling, and B. Painter. 1984. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob. Agents Chemother. 26:741-744.
15. Hooper, D. C. 2000. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin. Infect. Dis. 31(Suppl. 2):S24-S28.
16. Jacoby, G., V. Cattoir, D. Hooper, L. Martinez-Martinez, P. Nordmann, A. Pascual, L. Poirel, and M. Wang. 2008. qnr gene nomenclature. Antimicrob. Agents Chemother. 52:2297-2299.
17. Jacoby, G. A. 2005. Mechanisms of resistance to quinolones. Clin. Infect. Dis. 41(Suppl. 2):S120-S126.
18. Jacoby, G. A., N. Chow, and K. B. Waites. 2003. Prevalence of plasmid-mediated quinolone resistance. Antimicrob. Agents Chemother. 47:559-562.
19. Kahlmeter, G., D. F. Brown, F. W. Goldstein, A. P. MacGowan, J. W. Mouton, I. Odenholt, A. Rodloff, C. J. Soussy, M. Steinbakk, F. Soriano, and O. Stetsiouk. 2006. European Committee on Antimicrobial Susceptibility Testing (EUCAST) technical notes on antimicrobial susceptibility testing. Clin. Microbiol. Infect. 12:501-503.
20. Labat, F., O. Pradillon, L. Garry, M. Peuchmaur, B. Fantin, and E. Denamur. 2005. Mutator phenotype confers advantage in Escherichia coli chronic urinary tract infection pathogenesis. FEMS Immunol. Med. Microbiol. 44:317-321.
21. Lavilla, S., J. J. Gonzalez-Lopez, M. Sabate, A. Garcia-Fernandez, M. N. Larrosa, R. M. Bartolome, A. Carattoli, and G. Prats. 2008. Prevalence of qnr genes among extended-spectrum beta-lactamase-producing enterobacterial isolates in Barcelona, Spain. J. Antimicrob. Chemother. 61:291-295.
22. Lobel, B., A. Valot, V. Cattoir, O. Lemenand, and O. Gaillot. 2008. Comparison of antimicrobial susceptibility of 1,217 Escherichia coli isolates from women with hospital and community-acquired urinary tract infections. Presse Med. 37:746-750. (In French.)
23. Mahamat, A., J. P. Lavigne, P. Fabbro-Peray, J. M. Kinowski, J. P. Daures, and A. Sotto. 2005. Evolution of fluoroquinolone resistance among Escherichia coli urinary tract isolates from a French university hospital: application of the dynamic regression model. Clin. Microbiol. Infect. 11:301-306.
24. Mammeri, H., L. Poirel, and P. Nordmann. 2005. Bactericidal activity of fluoroquinolones against plasmid-mediated QnrA-producing Escherichia coli. Clin. Microbiol. Infect. 11:1048-1049.
25. Martinez-Martinez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799.
26. McCarron, B., and W. C. Love. 1997. Acalculous nontyphoidal salmonellal cholecystitis requiring surgical intervention despite ciprofloxacin therapy: report of three cases. Clin. Infect. Dis. 24:707-709.
27. Perichon, B., P. Courvalin, and M. Galimand. 2007. Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli. Antimicrob. Agents Chemother. 51:2464-2469. (Pubitemid 47047325)
28. Poirel, L., J. D. Pitout, L. Calvo, J. M. Rodriguez-Martinez, D. Church, and P. Nordmann. 2006. In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. Antimicrob. Agents Chemother. 50:1525-1527.
29. Poole, K. 2000. Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob. Agents Chemother. 44:2233-2241.
30. Preston, S. L., G. L. Drusano, A. L. Berman, C. L. Fowler, A. T. Chow, B. Dornseif, V. Reichl, J. Natarajan, and M. Corrado. 1998. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129. (Pubitemid 28068302)
31. Robicsek, A., G. A. Jacoby, and D. C. Hooper. 2006. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect. Dis. 6:629-640.
32. Robicsek, A., J. Strahilevitz, G. A. Jacoby, M. Macielag, D. Abbanat, C. H. Park, K. Bush, and D. C. Hooper. 2006. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med. 12:83-88.
33. Robicsek, A., J. Strahilevitz, D. F. Sahm, G. A. Jacoby, and D. C. Hooper. 2006. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50:2872-2874.
34. Rodriguez-Martinez, J. M., C. Pichardo, I. Garcia, M. E. Pachon-Ibanez, F. Docobo-Perez, A. Pascual, J. Pachon, and L. Martinez-Martinez. 2008. Activity of ciprofloxacin and levofloxacin in experimental pneumonia caused by Klebsiella pneumoniae deficient in porins, expressing active efflux and producing QnrA1. Clin. Microbiol. Infect. 14:691-697.
35. Rodriguez-Martinez, J. M., C. Velasco, I. Garcia, M. E. Cano, L. Martinez-Martinez, and A. Pascual. 2007. Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1. Antimicrob. Agents Chemother. 51:2236-2239.
36. Rubinstein, E., L. St Julien, J. Ramon, S. Dautrey, R. Farinotti, J. F. Huneau, and C. Carbon. 1994. The intestinal elimination of ciprofloxacin in the rat. J. Infect. Dis. 169:218-221.
37. Schentag, J. J. 2000. Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin. Infect. Dis. 31(Suppl. 2):S40-S44.
38. Shandil, R. K., R. Jayaram, P. Kaur, S. Gaonkar, B. L. Suresh, B. N. Mahesh, R. Jayashree, V. Nandi, S. Bharath, and V. Balasubramanian. 2007. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51:576-582.
39. Shin, J. H., H. J. Jung, J. Y. Lee, H. R. Kim, J. N. Lee, and C. L. Chang. 2008. High rates of plasmid-mediated quinolone resistance QnrB variants among ciprofloxacin-resistant Escherichia coli and Klebsiella pneumoniae from urinary tract infections in Korea. Microb. Drug Resist. 14:221-226.
40. Vasallo, F. J., P. Martin-Rabadan, L. Alcala, J. M. Garcia-Lechuz, M. Rodriguez-Creixems, and E. Bouza. 1998. Failure of ciprofloxacin therapy for invasive nontyphoidal salmonellosis. Clin. Infect. Dis. 26:535-536.